CDKN1A and cancer: The molecular mechanism of anti-cancer action of this compound was associated with the induction of cell cycle arrest at the G2/M phase through regulation of CDK2, CDK4, cyclin D1, and p21WAF1/CIP1 proteins’ expression and inhibition of mitogen-activated protein kinases of MAPK/ERK1/2 signaling cascade.